Maze Therapeutics, Inc.

Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing small-molecule precision medicines for renal, cardiovascular and related metabolic diseases, including obesity. It uses its Compass platform to link human genetic variants to disease biology and advance programs such as MZE829 and MZE782, while also monetizing select discovery assets through licensing and collaboration deals.

15.50

15.50

— Maze Therapeutics, Inc.
%
Clinical-stage therapeutic candidates0% Lead small-molecule drug programs being tested in humans for renal and CVRM diseases.
Discovery and preclinical pipeline0% Earlier-stage programs generated from the Compass platform and internal research.
Platform-enabled target discovery0% Human genetics and variant functionalization tools used to identify and validate targets.
Licensing and collaboration revenue100% Upfront payments, milestones and royalties from out-licensing selected programs.

Maze does not sell approved products today; its near-term counterparties are pharmaceutical partners and, eventually,...

  • Licensing and collaboration partnersprimary

    Biopharma companies that pay upfronts, milestones or royalties for selected targets and programs.

  • Patients with chronic kidney disease and related nephropathiesprimary

    Potential end users of MZE829, MZE782 and future renal therapies if approved.

  • Physicians and specialist prescriberssecondary

    Nephrologists and other clinicians who would adopt the therapy based on efficacy, safety and convenience.

  • Third-party payorssecondary

    Insurers and reimbursement bodies that determine access and pricing for approved medicines.

  • Patient advocacy organizationsemerging

    Groups that can support awareness, trial enrollment and eventual market acceptance.

Maze is headquartered in the United States and its development, regulatory and financing activities are primarily U.S...

  • •Headquartered and primarily operated in the United States
  • •Clinical development and FDA interaction are central to the business model
  • •Potential foreign regulatory filings may matter if programs expand internationally
  • •No product-sales geography is disclosed because the company is pre-commercial
  • •License and collaboration activity can create non-U.S. exposure over time

Maze’s strategy is to use human genetics and its Compass platform to identify disease-driving pathways, then advance...

01
Advance lead clinical programsshort-term

Clinical proof-of-concept is the main value driver for a pre-commercial biotech.

02
Broaden the pipeline through Compassmedium-term

A deeper pipeline reduces single-asset risk and increases partnering optionality.

03
Secure non-dilutive capital and partnershipsshort-term

The company expects continued losses and needs funding to reach later milestones.

Maze faces the classic risks of a clinical-stage biotech: clinical failure, safety issues, regulatory delays and the...

high

Clinical development failure

MZE829, MZE782 and other programs may not demonstrate sufficient safety or efficacy.

Scope
Lead pipeline value and future commercialization
Materiality
high
high

Funding shortfall and dilution

The company expects to require substantial additional capital before meaningful revenue.

Scope
Operating runway and pipeline continuity
Materiality
high
high

Regulatory and safety setbacks

FDA approval, REMS requirements or adverse events could delay or block development.

Scope
Clinical timelines and approval probability
Materiality
high
medium

Commercial market acceptance

Even approved therapies may not gain physician, patient or payor adoption.

Scope
Future product revenue and profitability
Materiality
medium
medium

Competitive pressure in CKD

Established RAAS, SGLT2 and GLP-1 therapies and new APOL1 entrants compete for the same patients.

Scope
Pricing power and market share
Materiality
medium
medium

Partner and spin-out governance risk

Joint ventures and spin-outs can create conflicts, execution issues and reputational exposure.

Scope
Non-core collaborations and target monetization
Materiality
medium
License revenue recognition
Can cause large period-to-period swings unrelated to core operating performance
R&D expense estimation
Directly affects operating loss and comparability across quarters
Going-concern and liquidity assumptions
Affects runway disclosure and financing risk assessment
Stock-based compensation and public-company costs
Influences reported losses and adjusted operating trends

Relay Therapeutics, Inc.

RLAY · Biological Products, (No Diagnostic Substances)

Gain Therapeutics, Inc.

GANX · Pharmaceutical Preparations

MapLight Therapeutics, Inc.

MPLT · Pharmaceutical Preparations

Voyager Therapeutics, Inc.

VYGR · Biological Products, (No Diagnostic Substances)

Compass Therapeutics, Inc.

CMPX · Biological Products, (No Diagnostic Substances)

Tango Therapeutics, Inc.

TNGX · Pharmaceutical Preparations

: 28/04/2026